Published in J Exp Med on March 26, 2007
Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol (2011) 2.93
IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog (2008) 2.01
Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A (2008) 1.96
Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to uncomplicated and severe Plasmodium falciparum malaria. PLoS Pathog (2009) 1.81
Posttranscriptional regulation of II10 gene expression allows natural killer cells to express immunoregulatory function. Immunity (2008) 1.65
IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol (2010) 1.59
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasis. Clin Vaccine Immunol (2012) 1.49
IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol (2009) 1.46
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology. PLoS Pathog (2016) 1.44
Malaria immunity in man and mosquito: insights into unsolved mysteries of a deadly infectious disease. Annu Rev Immunol (2014) 1.38
Neutrophils contribute to development of a protective immune response during onset of infection with Leishmania donovani. Infect Immun (2007) 1.36
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol Res (2010) 1.32
Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med (2013) 1.29
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis. PLoS Negl Trop Dis (2009) 1.29
B7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infections. PLoS Pathog (2009) 1.27
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20
Exposure-dependent control of malaria-induced inflammation in children. PLoS Pathog (2014) 1.16
IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog (2013) 1.15
Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol (2013) 1.14
Leishmaniasis, an emerging disease found in companion animals in the United States. Top Companion Anim Med (2009) 1.13
Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity (2010) 1.12
Intralesional regulatory T-cell suppressive function during human acute and chronic cutaneous leishmaniasis due to Leishmania guyanensis. Infect Immun (2009) 1.12
Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog (2008) 1.11
Immunobiology of visceral leishmaniasis. Front Immunol (2012) 1.10
Human immunodeficiency virus and leishmaniasis. J Glob Infect Dis (2010) 1.09
Immunological perspectives of leishmaniasis. J Glob Infect Dis (2010) 1.08
CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2013) 1.06
A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis (2010) 1.06
Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients. PLoS Negl Trop Dis (2011) 1.05
Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis. Curr Opin Infect Dis (2008) 1.05
Canine leishmaniasis in North America: emerging or newly recognized? Vet Clin North Am Small Anim Pract (2009) 1.05
Arginase activity - a marker of disease status in patients with visceral leishmaniasis in ethiopia. PLoS Negl Trop Dis (2013) 1.04
Immunologic indicators of clinical progression during canine Leishmania infantum infection. Clin Vaccine Immunol (2009) 1.02
A transient reversal of miRNA-mediated repression controls macrophage activation. EMBO Rep (2013) 1.01
Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front Immunol (2014) 1.00
Regulatory T cells suppress T cell activation at the pathologic site of human visceral leishmaniasis. PLoS One (2012) 1.00
IL-10-producing Th1 cells and disease progression are regulated by distinct CD11c⁺ cell populations during visceral leishmaniasis. PLoS Pathog (2012) 1.00
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunology (2015) 1.00
Restoration of IFNγR subunit assembly, IFNγ signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterol. PLoS Pathog (2011) 0.99
Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis. PLoS Negl Trop Dis (2011) 0.99
Immunopathogenesis of non-healing American cutaneous leishmaniasis and progressive visceral leishmaniasis. Semin Immunopathol (2012) 0.98
T helper1/t helper2 cells and resistance/susceptibility to leishmania infection: is this paradigm still relevant? Front Immunol (2012) 0.98
Progressive visceral leishmaniasis is driven by dominant parasite-induced STAT6 activation and STAT6-dependent host arginase 1 expression. PLoS Pathog (2012) 0.97
The immunobiology of Leishmania braziliensis infection. Front Immunol (2012) 0.97
Chronic viral infection promotes sustained Th1-derived immunoregulatory IL-10 via BLIMP-1. J Clin Invest (2014) 0.96
A human IL10 BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proc Natl Acad Sci U S A (2009) 0.94
Leishmania specific CD4 T cells release IFNγ that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis (2014) 0.93
Deception and manipulation: the arms of leishmania, a successful parasite. Front Immunol (2014) 0.93
Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am J Trop Med Hyg (2010) 0.93
Treatment with IP-10 induces host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice. Med Microbiol Immunol (2011) 0.93
The CD14+CD16+ inflammatory monocyte subset displays increased mitochondrial activity and effector function during acute Plasmodium vivax malaria. PLoS Pathog (2014) 0.92
Regulation of immunity during visceral Leishmania infection. Parasit Vectors (2016) 0.92
Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol (2013) 0.92
Visceral leishmaniasis and HIV coinfection in Latin America. PLoS Negl Trop Dis (2014) 0.92
Leishmania exosomes deliver preemptive strikes to create an environment permissive for early infection. Front Cell Infect Microbiol (2012) 0.91
Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites. J Trop Med (2011) 0.91
Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis. PLoS Negl Trop Dis (2012) 0.90
Vaccine Development Against Leishmania donovani. Front Immunol (2012) 0.90
Human visceral leishmaniasis is not associated with expansion or accumulation of Foxp3+ CD4 cells in blood or spleen. Parasite Immunol (2010) 0.89
Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl Trop Dis (2013) 0.89
DNA vaccination with KMP11 and Lutzomyia longipalpis salivary protein protects hamsters against visceral leishmaniasis. Acta Trop (2011) 0.89
Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis (2014) 0.88
T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine. PLoS Pathog (2013) 0.88
Growth factor and Th2 cytokine signaling pathways converge at STAT6 to promote arginase expression in progressive experimental visceral leishmaniasis. PLoS Pathog (2014) 0.87
Signals for the execution of Th2 effector function. Cytokine (2009) 0.86
Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials. Infect Immun (2009) 0.86
The Regulation of CD4(+) T Cell Responses during Protozoan Infections. Front Immunol (2014) 0.85
Antigen-Pulsed CpG-ODN-Activated Dendritic Cells Induce Host-Protective Immune Response by Regulating the T Regulatory Cell Functioning in Leishmania donovani-Infected Mice: Critical Role of CXCL10. Front Immunol (2014) 0.85
Abortive T follicular helper development is associated with a defective humoral response in Leishmania infantum-infected macaques. PLoS Pathog (2014) 0.85
Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections. BMC Immunol (2014) 0.83
IL-10-IFN-γ double producers CD4+ T cells are induced by immunization with an amastigote stage specific derived recombinant protein of Trypanosoma cruzi. Int J Biol Sci (2011) 0.83
Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen. PLoS Negl Trop Dis (2014) 0.82
Deficiency of p110δ isoform of the phosphoinositide 3 kinase leads to enhanced resistance to Leishmania donovani. PLoS Negl Trop Dis (2014) 0.82
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications. Front Immunol (2014) 0.82
Involvement of CD4⁺ Foxp3⁺ regulatory T cells in persistence of Leishmania donovani in the liver of alymphoplastic aly/aly mice. PLoS Negl Trop Dis (2012) 0.82
Whole blood assay and visceral leishmaniasis: Challenges and promises. Immunobiology (2014) 0.82
A Petri net model of granulomatous inflammation: implications for IL-10 mediated control of Leishmania donovani infection. PLoS Comput Biol (2013) 0.82
Antimony resistant Leishmania donovani but not sensitive ones drives greater frequency of potent T-regulatory cells upon interaction with human PBMCs: role of IL-10 and TGF-β in early immune response. PLoS Negl Trop Dis (2014) 0.82
New means of canine leishmaniasis transmission in north america: the possibility of transmission to humans still unknown. Interdiscip Perspect Infect Dis (2009) 0.82
Characterization of regulatory T cell (Treg) function in patients infected with Leishmania braziliensis. Hum Immunol (2013) 0.81
Evaluation of T cell responses in healing and nonhealing leishmaniasis reveals differences in T helper cell polarization ex vivo and in vitro. Parasite Immunol (2009) 0.81
Leishmania infantum amastigotes trigger a subpopulation of human B cells with an immunoregulatory phenotype. PLoS Negl Trop Dis (2015) 0.81
Enhanced expression of Toll-like receptors 2 and 4, but not 9, in spleen tissue from patients with visceral leishmaniasis. Parasite Immunol (2014) 0.80
Is the polymorphism at position -1082 of IL-10 gene associated with visceral leishmaniasis? Iran J Public Health (2014) 0.79
The involvement of TLR2 and TLR4 in cytokine and nitric oxide production in visceral leishmaniasis patients before and after treatment with anti-leishmanial drugs. PLoS One (2015) 0.79
Clinical severity of visceral leishmaniasis is associated with changes in immunoglobulin g fc N-glycosylation. MBio (2014) 0.79
Tr-1-like CD4+CD25-CD127-/lowFOXP3- cells are the main source of interleukin 10 in patients with cutaneous leishmaniasis due to Leishmania braziliensis. J Infect Dis (2014) 0.79
Is the IL-10 -819 polymorphism associated with visceral leishmaniasis? Inflammation (2013) 0.79
Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis (2011) 0.78
T cell hypo-responsiveness against Leishmania major in MAP kinase phosphatase (MKP) 2 deficient C57BL/6 mice does not alter the healer disease phenotype. PLoS Negl Trop Dis (2013) 0.78
Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors (2016) 0.78
The host-protective effect of arabinosylated lipoarabinomannan against Leishmania donovani infection is associated with restoration of IFN-γ responsiveness. PLoS One (2015) 0.78
Highly heterogeneous, activated, and short-lived regulatory T cells during chronic filarial infection. Eur J Immunol (2014) 0.78
Post-Genomics and Vaccine Improvement for Leishmania. Front Microbiol (2016) 0.78
Leishmania spp. Proteome Data Sets: A Comprehensive Resource for Vaccine Development to Target Visceral Leishmaniasis. Front Immunol (2014) 0.78
Transcriptional profiling of the spleen in progressive visceral leishmaniasis reveals mixed expression of type 1 and type 2 cytokine-responsive genes. BMC Immunol (2014) 0.77
Lipopolysaccharide-Induced Cellular Activation May Participate in the Immunopathogenesis of Visceral Leishmaniasis Alone or in HIV Coinfection. Int J Microbiol (2012) 0.77
IL-27 and TGFβ mediated expansion of Th1 and adaptive regulatory T cells expressing IL-10 correlates with bacterial burden and disease severity in pulmonary tuberculosis. Immun Inflamm Dis (2015) 0.77
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity (2005) 23.00
CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature (2002) 11.79
CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med (2007) 4.66
Conventional T-bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10 during intracellular protozoan infection. J Exp Med (2007) 4.47
IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest (2004) 3.69
The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 3.63
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 3.62
Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol (2004) 3.61
Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol (2004) 3.58
Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol (2004) 3.50
Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood (2004) 3.35
Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest (1993) 3.28
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens. J Exp Med (2006) 3.22
The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol (2005) 3.21
IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest (2000) 3.19
An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology (2004) 3.18
CD4+ Tregs and immune control. J Clin Invest (2004) 2.85
In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest (1993) 2.84
Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood (2003) 2.65
Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis. J Exp Med (2002) 2.60
An analysis of T cell responsiveness in Indian kala-azar. J Immunol (1987) 2.56
A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med (2005) 2.50
Vaccination against cutaneous leishmaniasis in a murine model. I. Induction of protective immunity with a soluble extract of promastigotes. J Immunol (1987) 2.43
Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med (1996) 2.36
Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol (1994) 2.25
Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun (2003) 2.19
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
CD4(+) T cell clones producing both interferon-gamma and interleukin-10 predominate in bronchoalveolar lavages of active pulmonary tuberculosis patients. Clin Immunol (1999) 2.01
Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol (1983) 2.00
IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol (2001) 1.99
Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol (2003) 1.91
IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol (1995) 1.69
Morphology of the spleen and lymph nodes in fatal visceral leishmaniasis. Immunology (1977) 1.68
Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol (2002) 1.54
Identification of a T cell subset capable of both IFN-gamma and IL-10 secretion in patients with chronic Borrelia burgdorferi infection. J Immunol (1998) 1.53
Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis (1998) 1.49
Distinct roles for IL-6 and IL-12p40 in mediating protection against Leishmania donovani and the expansion of IL-10+ CD4+ T cells. Eur J Immunol (2006) 1.44
Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis (2005) 1.39
Advances in the treatment of leishmaniasis. Curr Opin Infect Dis (2002) 1.27
Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis (1993) 1.23
Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis. J Infect Dis (2003) 1.20
Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun (2005) 1.09
Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani. Clin Exp Immunol (2005) 1.08
Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz J Med Biol Res (2003) 1.03
T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol (2005) 1.02
Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection. Exp Parasitol (2001) 1.01
Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg (2001) 0.99
Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. Rev Inst Med Trop Sao Paulo (1998) 0.97
Leishmania chagasi antigens recognized in cured visceral leishmaniasis and asymptomatic infection. Am J Trop Med Hyg (1992) 0.95
Flow cytometric analysis of normal and reactive spleen. Mod Pathol (2004) 0.91
Clinico-hematological characteristics in patients with kala azar. A study from north-west India. Trop Geogr Med (1991) 0.88
The fate of heterologous CD4+ T cells during Leishmania donovani infection. Eur J Immunol (2005) 0.84
Fine needle aspiration cytology of the spleen in visceral leishmaniasis. Acta Cytol (1993) 0.79
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke (2003) 7.75
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol (2009) 6.62
In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science (2008) 5.09
CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med (2007) 4.66
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol (2009) 4.51
Phagosomes are competent organelles for antigen cross-presentation. Nature (2003) 3.97
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Unique gene expression profiles of human macrophages and dendritic cells to phylogenetically distinct parasites. Blood (2003) 2.65
Role for CD4(+) CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and control of concomitant immunity. J Exp Med (2004) 2.57
Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56
Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol (2006) 2.32
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
Image-guided tumor ablation: standardization of terminology and reporting criteria. J Vasc Interv Radiol (2009) 2.29
Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol (2007) 2.23
Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol (2006) 2.22
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol (2002) 2.16
High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06
The American "board" of vascular medicine: questions and concerns. J Vasc Interv Radiol (2005) 2.02
Quantification of the infectious dose of Leishmania major transmitted to the skin by single sand flies. Proc Natl Acad Sci U S A (2008) 1.98
Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Guidelines for the reporting of renal artery revascularization in clinical trials. J Vasc Interv Radiol (2002) 1.75
Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol (2006) 1.75
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67
Genetic characterization of glucose transporter function in Leishmania mexicana. Proc Natl Acad Sci U S A (2003) 1.64
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health (2008) 1.63
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol Rev (2006) 1.61
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Leishmania disease development depends on the presence of apoptotic promastigotes in the virulent inoculum. Proc Natl Acad Sci U S A (2006) 1.58
Endocrine changes in male HIV patients. J Assoc Physicians India (2011) 1.56
Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50
Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol (2008) 1.49
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. Cardiovasc Intervent Radiol (2004) 1.48
Quality improvement guidelines for percutaneous transhepatic cholangiography and biliary drainage. J Vasc Interv Radiol (2003) 1.48
Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop (2009) 1.47
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46
IL-27 regulates IL-10 and IL-17 from CD4+ cells in nonhealing Leishmania major infection. J Immunol (2009) 1.46
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Training guidelines for intra-arterial catheter-directed treatment of acute ischemic stroke: a statement from a special writing group of the Society of Interventional Radiology. J Vasc Interv Radiol (2009) 1.42
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Denied in Canada: why we need a global strategic plan for interventional radiology. J Vasc Interv Radiol (2008) 1.41
Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. Am J Trop Med Hyg (2006) 1.40
Retrieval of inferior vena cava filters after prolonged indwelling time. Arch Intern Med (2011) 1.40
Quality improvement guidelines for percutaneous nephrostomy. J Vasc Interv Radiol (2003) 1.37
Quality improvement guidelines for the reporting and archiving of interventional radiology procedures. J Vasc Interv Radiol (2003) 1.37
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics (2006) 1.36
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health (2006) 1.35
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India). BMC Gastroenterol (2008) 1.34
Society of Interventional Radiology quality improvement guidelines for percutaneous vertebroplasty. J Vasc Interv Radiol (2003) 1.34
Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. BMC Infect Dis (2006) 1.33
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol (2010) 1.32
The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health (2010) 1.30
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol (2009) 1.29
Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg (2007) 1.29
Trial design and reporting standards for intraarterial cerebral thrombolysis for acute ischemic stroke. J Vasc Interv Radiol (2003) 1.27
Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol (2009) 1.27
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis (2012) 1.27
Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother (2008) 1.26
MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J Invest Dermatol (2011) 1.26
The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol (2009) 1.25
Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access. J Vasc Interv Radiol (2003) 1.23
Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg (2009) 1.22
Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol (2006) 1.22
Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine (2002) 1.22
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother (2011) 1.19
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19